Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie

Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie
The Ischemic Stroke market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ischemic Stroke pipeline products will significantly revolutionize the Ischemic Stroke market dynamics.

DelveInsight’s “Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ischemic Stroke, historical and forecasted epidemiology as well as the Ischemic Stroke market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


To Know in detail about the Ischemic Stroke market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ischemic Stroke Market Forecast


Some of the key facts of the Ischemic Stroke Market Report: 

  • The Ischemic Stroke market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical study for AB126, aimed at addressing acute ischemic stroke, during the initial six months of 2024. This determination follows the clearance by the US Food and Drug Administration (FDA) of the company’s investigational new drug (IND) application pertaining to its primary program, AB126.
  • As per the study conducted by Edward C Jauch et. al., nearly 800,000 people suffer from strokes each year in the United States and 82–92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability 
  • According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke each year. Of these, 5 million die, and another 5 million are left permanently disabled. 
  • As per Stroke Association of the United Kingdom, Up to 25% of childhood Ischemic strokes are linked to congenital heart disease 
  • Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others 
  • Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others 
  • The Ischemic Stroke epidemiology based on gender analyzed that men are at higher risk for Ischemic Stroke than women


Ischemic Stroke Overview

Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- amass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.


Get a Free sample for the Ischemic Stroke Market Report:


Ischemic Stroke Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Ischemic Stroke Epidemiology Segmentation:

The Ischemic Stroke market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Ischemic Stroke
  • Prevalent Cases of Ischemic Stroke by severity
  • Gender-specific Prevalence of Ischemic Stroke
  • Diagnosed Cases of Episodic and Chronic Ischemic Stroke


Download the report to understand which factors are driving Ischemic Stroke epidemiology trends @ Ischemic Stroke Epidemiological Insights


Ischemic Stroke Market  

The dynamics of the Ischemic Stroke market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.


Ischemic Stroke Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ischemic Stroke market or expected to get launched during the study period. The analysis covers Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ischemic Stroke Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Ischemic Stroke Therapies and Key Companies

  • BMS986177: Bristol-Myers Squibb
  • LT-3001: Lumosa Therapeutics
  • Elezanumab: Abbvie
  • MultiStem: Athersys/Healios K.K.


To know more about Ischemic Stroke treatment, visit @ Ischemic Stroke Medications


Scope of the Ischemic Stroke Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others
  • Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others
  • Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
  • Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Ischemic Stroke Unmet Needs, KOL’s views, Analyst’s views, Ischemic Stroke  Market Access and Reimbursement


Discover more about therapies set to grab major Ischemic Stroke market share @ Ischemic Stroke market forecast


Table of Contents 

1. Ischemic Stroke Market Report Introduction

2. Executive Summary for Ischemic Stroke

3. SWOT analysis of Ischemic Stroke

4. Ischemic Stroke Patient Share (%) Overview at a Glance

5. Ischemic Stroke Market Overview at a Glance

6. Ischemic Stroke Disease Background and Overview

7. Ischemic Stroke Epidemiology and Patient Population

8. Country-Specific Patient Population of Ischemic Stroke 

9. Ischemic Stroke Current Treatment and Medical Practices

10. Ischemic Stroke Unmet Needs

11. Ischemic Stroke Emerging Therapies

12. Ischemic Stroke Market Outlook

13. Country-Wise Ischemic Stroke Market Analysis (2019–2032)

14. Ischemic Stroke Market Access and Reimbursement of Therapies

15. Ischemic Stroke Market drivers

16. Ischemic Stroke Market barriers

17.  Ischemic Stroke Appendix

18. Ischemic Stroke Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States